SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+31.2%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(+26%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-15.61%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
104
New
30
Increased
28
Reduced
25
Closed
13
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$43.7M |
| 2 |
TG Therapeutics
TGTX
|
$38.3M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$23.2M |
| 4 |
Keros Therapeutics
KROS
|
$18.1M |
| 5 |
Biogen
BIIB
|
$15.7M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$255M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$46.4M |
| 3 |
GSK
GSK
|
$41.1M |
| 4 |
Viking Therapeutics
VKTX
|
$30.3M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$29.3M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Olema Pharmaceuticals
OLMA
$375M
| $7.45M | 0.55% | +658,000 | New | +$7.45M |
|
52
GeneDx Holdings
WGS
$3.72B
| $7.15M | 0.53% | 783,376 +723,376 | +1,206% | +$6.6M |
|
53
Bausch Health
BHC
$2.74B
| $7.11M | 0.53% | +670,000 | New | +$7.11M |
|
54
MannKind Corp
MNKD
$1.41B
| $7.06M | 0.52% | +1,558,537 | New | +$7.06M |
|
55
MindMed
MNMD
$676M
| $7.05M | 0.52% | +750,237 | New | +$7.05M |
|
56
Insmed
INSM
$28.8B
| $6.78M | 0.5% | 250,000 +82,900 | +50% | +$2.25M |
|
57
Fate Therapeutics
FATE
$120M
| $6.39M | 0.47% | +870,000 | New | +$6.39M |
|
58
X4 Pharmaceuticals
XFOR
$84.2M
| $6.37M | 0.47% | +4,579,926 | New | +$6.37M |
|
59
4D Molecular Therapeutics
FDMT
$288M
| $6.28M | 0.47% | 197,098 +151,350 | +331% | +$4.82M |
|
60
Viridian Therapeutics
VRDN
$1.5B
| $5.95M | 0.44% | 340,000 +202,000 | +146% | +$3.54M |
|
61
Janux Therapeutics
JANX
$1.37B
| $5.94M | 0.44% | +157,800 | New | +$5.94M |
|
62
Oric Pharmaceuticals
ORIC
$994M
| $5.79M | 0.43% | +421,000 | New | +$5.79M |
|
|
63
Viking Therapeutics
VKTX
$3.04B
| $5.5M | 0.41% | 67,121 -369,079 | -85% | -$30.3M |
|
|
CMPS
64
Compass Pathways
CMPS
$424M
| $4.71M | 0.35% | 565,550 -399,000 | -41% | -$3.32M |
|
65
KalVista Pharmaceuticals
KALV
$678M
| $4.58M | 0.34% | +386,000 | New | +$4.58M |
|
|
RGLS
66
DELISTED
Regulus Therapeutics
RGLS
| $4.5M | 0.33% | +1,562,500 | New | +$4.5M |
|
|
BCYC
67
Bicycle Therapeutics
BCYC
$511M
| $3.81M | 0.28% | 153,000 +58,000 | +61% | +$1.44M |
|
68
InspireMD
NSPR
$102M
| $3.27M | 0.24% | 1,378,128 | – | – |
|
69
CalciMedica
CALC
$37.7M
| $3.26M | 0.24% | +783,904 | New | +$3.26M |
|
70
Nkarta
NKTX
$151M
| $3.24M | 0.24% | +300,000 | New | +$3.24M |
|
71
Dianthus Therapeutics
DNTH
$759M
| $3M | 0.22% | +100,000 | New | +$3M |
|
72
CervoMed
CRVO
$83.7M
| $2.95M | 0.22% | +126,614 | New | +$2.95M |
|
73
Taysha Gene Therapies
TSHA
$797M
| $2.65M | 0.2% | +925,000 | New | +$2.65M |
|
74
Praxis Precision Medicines
PRAX
$958M
| $2.27M | 0.17% | +37,268 | New | +$2.27M |
|
75
Evolus
EOLS
$494M
| $2.24M | 0.17% | +160,000 | New | +$2.24M |
|